Results 111 to 120 of about 2,249 (191)

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

Journal of Dermatological Treatment
Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch ...
Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold   +9 more
doaj   +1 more source

Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis [PDF]

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients’ quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to ...
Cataldo Patruno, Caterina Foti, Giampiero Girolomoni, Luca Stingeni, Paolo Amerio, Silvia Ferrucci   +5 more
core   +1 more source

Successful Lebrikizumab Therapy in Two Patients With Atopic Dermatitis Resistant to Multiple Therapies

JEADV Clinical Practice
The treatment landscape for moderate‐to‐severe atopic dermatitis (AD) has evolved significantly with the introduction of novel targeted therapies addressing specific pathogenic mechanisms of the disease.
Elena Ippoliti, Niccolò Gori, Benedetta Ambrosio, Giulia Coscarella, Maria Vittoria Cannizzaro, Ketty Peris   +5 more
doaj   +1 more source

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials

Acta Dermato-Venereologica
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI).
Diamant Thaçi, Luis Puig, Sei-ichiro Motegi, Kim Papp, Linda Stein Gold, Leon Kircik, Howard Sofen, Pablo Fernández-Peñas, Pedro Herranz, Christian Vestergaard, Yu-Huei Huang, Martin Dossenbach, Hany Elmaraghy, Gaia Gallo, Maria Jose Rueda, Marta Casillas, Chao Yang, Helena Agell, Meritxell Falqués, Audrey Nosbaum   +19 more
doaj   +1 more source

Lebrikizumab [PDF]

, 2020
openaire   +1 more source

Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis

JAAD International, 2023
Rose Alraddadi, MD, Abdulrahman H. Alsamadani, MD, Mulham A. Kalantan, MD, Yara E. Aljefri, MD, Hadeel A. Maaddawi, MD, Athoub N. Kadasa, MD, Rahaf F. Alturkistani, MD, Abdulhadi H. Jfri, MD, MSc   +7 more
doaj   +1 more source

IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents

Journal of International Medical Research
Atopic dermatitis (AD) is a common, chronic, and recurrent inflammatory skin condition that affects a considerable portion of the population, and is particularly prevalent among children.
Carlos Teixeira, Orhan Yilmaz, Diana Bernardo, Tiago Torres   +3 more
doaj   +1 more source

Circulation [PDF]

Spurred by advances in processing power, memory, storage, and an unprecedented wealth of data, computers are being asked to tackle increasingly complex learning tasks, often with astonishing success. Computers have now mastered a popular variant of poker,

core  

Correction: Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice. [PDF]

Dermatol Ther (Heidelb)
Stavropoulos N, Myszkowski D, Braß D, Dervenis V, Poungoura E, Stockfleth E.   +5 more
europepmc   +1 more source

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents. [PDF]

Cureus
Babul A, Mehta D, Soliman Y, Hussain M, Babul N.   +4 more
europepmc   +1 more source